Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHVNQM)

• Drug Name: 3-methyl-2(1H)-thioxo-4(3H)-quinazolinone Drug Info
• Synonyms: 1705-09-5; 2-mercapto-3-methylquinazolin-4(3H)-one; 2-Mercapto-3-methyl-3H-quinazolin-4-one; CHEMBL460734; 3-methyl-2-sulfanylidene-1H-quinazolin-4-one; 2-mercapto-3-methyl-3,4-dihydroquinazolin-4-one; 3-methyl-2-thioxo-2,3-dihydroquinazolin-4(1H)-one; 3-Methyl-2-thioxo-2,3-dihydro-1H-quinazolin-4-one; 4(1H)-Quinazolinone, 2,3-dihydro-3-methyl-2-thioxo-; 3-methyl-2-thioxo-1H-quinazolin-4-one; 3-methyl-2-thioxo-2,3-dihydro-4(1H)-quinazolinone; 3-methyl-2-sulfanylquinazolin-4(3H)-one

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 747056
  CAS Number: CAS 1705-09-5
  TTD Drug ID: DMHVNQM

Molecule-Related Drug Atlas

Drug(s) Targeting Monoamine oxidase type A (MAO-A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Moclobemide	DMNZWL7	Depression	6A70-6A7Z	Approved	[2]
Tranylcypromine	DMGB5RE	Major depressive disorder	6A70.3	Approved	[3]
Clorgyline	DMCEUJD	Parkinson disease	8A00.0	Approved	[4]
Isocarboxazid	DMAF1NB	Depression	6A70-6A7Z	Approved	[5]
TRYPTAMINE	DMAFPHB	N. A.	N. A.	Phase 3	[6]
Psoralen	DMIZJ8M	N. A.	N. A.	Phase 3	[7]
CHF-3381	DMQ2O8V	Neuropathic pain	8E43.0	Phase 2	[8]
Ladostigil	DMJSY3Q	Alzheimer disease	8A20	Phase 2	[9]
CX157	DMS2WB5	Mood disorder	6A60-6E23	Phase 2	[10]
PIPERINE	DMYEAB1	Vitiligo	ED63.0	Phase 1/2	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Monoamine oxidase type A (MAO-A)	TT3WG5C	AOFA_HUMAN	Inhibitor	[1]

References

• [1] New pyrazoline bearing 4(3H)-quinazolinone inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A ... Bioorg Med Chem. 2009 Jan 15;17(2):675-89.
• [2] Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings. Hum Psychopharmacol. 2002 Dec;17(8):401-5.
• [3] Tramadol and another atypical opioid meperidine have exaggerated serotonin syndrome behavioural effects, but decreased analgesic effects, in genetically deficient serotonin transporter (SERT) mice. Int J Neuropsychopharmacol. 2009 Mar 11:1-11.
• [4] Further investigation into the mechanism of tachykinin NK(2) receptor-triggered serotonin release from guinea-pig proximal colon. J Pharmacol Sci. 2009 May;110(1):122-6.
• [5] MAOIs in the contemporary treatment of depression. Neuropsychopharmacology. 1995 May;12(3):185-219.
• [6] Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
• [7] Inhibition of rat brain monoamine oxidase activities by psoralen and isopsoralen: implications for the treatment of affective disorders. Pharmacol Toxicol. 2001 Feb;88(2):75-80.
• [8] Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
• [9] Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr Drug Targets. 2012 Apr;13(4):483-94.
• [10] Reversible inhibitors of monoamine oxidase-A (RIMAs): robust, reversible inhibition of human brain MAO-A by CX157. Neuropsychopharmacology. 2010 Feb;35(3):623-31.
• [11] Proposed structural basis of interaction of piperine and related compounds with monoamine oxidases. Bioorg Med Chem Lett. 2010 Jan 15;20(2):537-40.